Gene therapy for bypass graft failure and restenosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue 5-6, 2002, Pages 389-391

  Baker, Andrew H ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Gene therapy; Nitric oxide; Oligonucleotides; Restenosis; Stents; TIMPs; Vein grafts

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NITRIC OXIDE SYNTHASE;

BYPASS SURGERY; CELL POPULATION; CLINICAL TRIAL; CONFERENCE PAPER; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GRAFT FAILURE; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; ANIMAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; REVIEW; TREATMENT FAILURE;

ANIMALS; CORONARY ARTERY BYPASS; CORONARY DISEASE; CORONARY RESTENOSIS; GENE THERAPY; HUMANS; TREATMENT FAILURE;

EID: 0142135534     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073606     Document Type: Conference Paper

References (6)

1. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296-304.
2. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Eshan A, Dell'Acqua G, Dzau, V. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. The Lancet 1999;354:1493-1498.
3. West N, Qian H, Guzik T, Black E, Cai S, George S, Channon, KM. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling. Circulation 2001;104:1526-1532.
4. Khurana R, Martin JF, Zachary I. Gene therapy for cardiovascular disease: A case for cautious optimism. Hypertension 2001;38:1210-1216.
5. Klugherz B, Song C, Defelice S, Cui X, Lu Z, Connolly J, Hinston JT, Wilensky, RL, Levy RJ. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Human Gene Therapy 2002;13:443-454.
6. Oka K, Pastore L, Kim I, Merched A, Nomura S, Lee H, Merched-Sauvage M, Arden-Riley C, Lee B, Finegold M, Beaudet A, Chan, L. Long term stable correction of low-desity lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circ 2001;103:1274-1281.